Table 1 Effect of mAb 4A2 on the Induction and Clinical Signs in EAE

From: Inhibition of Experimental Allergic Encephalomyelitis with an Antibody that Recognizes a Novel Antigen Expressed on Lymphocytes, Endothelial Cells, and Microglia

Parametera

Control

4A2

4A2 2 Daysb

Incidence of tail paralysis

11/11

6/12

2/4

Incidence of hind leg paralysis

8/10

0/12

0/4

Maximal clinical severity

1.9 ± 0.4 (11)

0.4 ± 0.1 (12)

0.6 ± 0.2 (4)

Duration of illness

3.6 ± 0.1 (9)

1.6 ± 0.4 (12)

1.8 ± 0.8 (4)

Overall illness scorec

7.3 ± 0.7 (9)

3.5 ± 1.2 (9)

2.5 ± 1.3 (4)

Average weight loss

20.6 ± 1.6 (9)

6.3 ± 2.3 (12)

14.0 ± 5.9 (4)

  1. aa Data presented here represent the mean ± se of the mean. () represents the number of animals per data point. In some experiments, for histological studies of initiation and peak inflammation, control and 4A2-treated animals were killed. All other animals were killed on day 8 after receiving EP-specific CD4+ T cells.
  2. bb These animals received one dose of the 4A2 mAb 2 days after injection of EP-specific CD4+ T cells. 4A2 animals represent animals that received 1 mg ip of SAS precipitated, protein G purified, mAb. Control animals represent animals that received saline (n = 9) or 1 mg IgG1 clarified MOPC1 ascites (n = 2).
  3. cc Numbers represent product of (number of days animal was sick) × (number of days animal was at maximum level of illness).
Back to article page